IL-17A increases PD-L1 expression through the p65/NRF1/miR-15b-5p axis and promotes resistance to anti-PD-1 therapy, and IL-17F might be associated with a favorable overall survival in pancreatic cancer patients who were treated with gemcitabine [105,106]. Here, IL17A is linked to pancreatic neoplasm.